NASDAQ:LIFE - Get Free Report ) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01, Yahoo Finance reports. The company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.11 million.
Get aTyr Pharma alerts:
Sign Up
aTyr Pharma Trading Up 0.6 % Shares of LIFE stock traded up $0.01 on Friday, hitting $1.61. The stock had a trading volume of 258,118 shares, compared to its average volume of 498,541. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.27 and a quick ratio of 6.27. The firm has a market capitalization of $109.38 million, a P/E ratio of -1.68 and a beta of 1.27. aTyr Pharma has a 1 year low of $1.08 and a 1 year high of $2.70. The company's 50 day moving average price is $1.78 and its 200-day moving average price is $1.55.
Analysts Set New Price Targets LIFE has been the topic of a number of research analyst reports. Royal Bank of Canada reduced their target price on aTyr Pharma from $19.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, March 15th. HC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of aTyr Pharma in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $23.67.
View Our Latest Report on LIFE
About aTyr Pharma (
Get Free Report )
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider aTyr Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.
While aTyr Pharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate . These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
